RxDoctor Payments Data

Geoffrey Gaunay, MD

Urology · Lancaster, PANPI 1629394150

Payments from drug & device makers

$8,568in general payments, 2019–2025

Across 335 payments — averaging $25.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Dendreon Pharmaceuticals LLC$2K
  • Astellas Pharma US Inc$724
  • Cipla USA Inc.$638
  • Boston Scientific$494
  • Sumitomo Pharma America, Inc.$473
  • Urogen Pharma, Inc.$472
  • plus $4K from 39 others

What the payments were for

  • Speaking & faculty fees$150%
  • Food & beverage$8,39998%
  • Education$1532%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,568 in reported general payments places this provider in the 75th percentile of 596 urology providers in Pennsylvania.

See all urology providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$206,333
Medicare patients
672
Services billed
5,117

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Thiola EcTiopronin25$216,252
OrgovyxRelugolix46$123,089
MyrbetriqMirabegron61$48,734
GemtesaVibegron14$13,134
ElmironPentosan Polysulfate Sodium13$11,825
Potassium Citrate ErPotassium Citrate90$9,035
Trospium Chloride ErTrospium Chloride34$6,189
Tamsulosin Hcl353$5,026
Finasteride265$4,011
Alfuzosin Hcl ErAlfuzosin Hcl139$3,482
Methenamine Hippurate26$3,344
Dutasteride49$1,802
Dutasteride-TamsulosinDutasteride/Tamsulosin Hcl12$1,784
Oxybutynin Chloride ErOxybutynin Chloride50$1,304
Trimethoprim26$958

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Orgovyx, Gemtesa$473$136,22260 claims
Astellas Pharma US IncMyrbetriq$724$48,73461 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 596 urology providers in Pennsylvania.

Other urology in Lancaster

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →